News

Marcos-Gragera group

Checking the effectiveness of drugs with real-world epidemiological data helps determine their benefit to the patient

Researchers from the Descriptive and analytical epidemiology of cancer group at the Josep Carreras Leukaemia Research Institute have participated in a study that has compared the effectiveness data of tyrosine kinase inhibitors (TKIs) declared in randomized clinical trials, with their action on real population based on epidemiological data. The research proves that the results of the trials, despite being carried out under ideal, highly controlled conditions, are correctly translated to the general population, with all its complexity, demonstrating the effectiveness of TKIs in the real world.

Read more
Look-Alikes

Biological explanation discovered of why we all have a “look-alike” person

Researchers at the Josep Carreras Leukaemia Research Institute, led by Dr. Manel Esteller, have discovered that extremely similar but unrelated people share genetic characteristics in the genes responsible for the formation of facial features. This explains, from a biological point of view, the appearance of "doubles" in remote places, and could help in the identification of a person from genetic material, which would be of great interest in forensic and legal medicine.

Read more

A new project aims to shed new light on a frequent form of leukemia in Down Syndrome children

The American Society of Hematology (ASH) has selected a project led by Dr. Sergi Cuartero, researcher at the Josep Carreras Leukaemia Research Institute, to receive the 2022 ASH Global Research Award. Dr. Cuartero is one of 13 talented early-career investigators selected for this honor. The project aims to better understand the molecular basis of myeloid leukemia of Down Syndrome (ML-DS) and contribute to the identification of novel actionable targets for therapeutic use in ML-DS.

Read more
Oscar Molina 2021

A new method developed by researchers from the Josep Carreras Institute predicts childhood hyperdiploid B-ALL relapse risk

An international research team coordinated by Dr. Oscar Molina and Dr. Pablo Menéndez, from the Josep Carreras Leukaemia Research Institute, identifies chromosomal abnormalities associated to relapse in a frequent subset of B-cell Acute Lymphoblastic Leukemia (B-ALL), a severe condition affecting especially children. This finding may help identify those patients at a higher risk of relapse at diagnosis to direct them to more appropriate treatment options and anticipate the cancer comeback.

Read more